

000 001 002 003 004 005 006 007 008 009 010 011 012 013 014 015 016 017 018 019 020 021 022 023 024 025 026 027 028 029 030 031 032 033 034 035 036 037 038 039 040 041 042 043 044 045 046 047 048 049 050 051 052 053 ABCONFORMER: PHYSICS-INSPIRED SLIDING ATTENTION FOR ANTIBODY-ANTIGEN INTERFACE PREDICTION

006
007 **Anonymous authors**
008 Paper under double-blind review

010 011 ABSTRACT 012

013 Accurate prediction of antibody-antigen (Ab-Ag) interfaces is critical for vac-
014 cine design, immunodiagnostics and therapeutic antibody development. However,
015 achieving reliable predictions from sequences alone remains a challenge. In this
016 paper, we present ABCONFORMER, a model based on the Conformer backbone
017 that captures both local and global features of a biosequence. To accurately cap-
018 ture Ab-Ag interactions, we introduced the physics-inspired sliding attention, en-
019 abling residue-level contact recovery without relying on three-dimensional struc-
020 tural data. ABCONFORMER can accurately predict paratopes and epitopes given
021 the antibody and antigen sequence, and predict pan-epitopes on the antigen with-
022 out antibody information. In comparison experiments, ABCONFORMER achieves
023 state-of-the-art performance on a recent SARS-CoV-2 Ab-Ag dataset, and sur-
024 passes widely used sequence-based methods for antibody-agnostic epitope pre-
025 diction. Ablation studies further quantify the contribution of each component,
026 demonstrating that, compared to conventional cross-attention, sliding attention
027 significantly enhances the precision of epitope prediction. To facilitate repro-
028 ducibility, we will release the code under an open-source license upon acceptance.

029 030 1 INTRODUCTION 031

032 Antibodies are Y-shaped glycoproteins with two arms (Fab fragments) and a stem (Fc fragment),
033 where the arms contain antigen-binding sites at their tips and are connected to the stem through a
034 flexible hinge. Each antibody has two identical heavy (Ab-H) and light (Ab-L) chains, with each
035 chain containing an N-terminal variable domain (VH in heavy, VL in light) followed by constant
036 domains (CH1–CH3 in heavy, CL in light). Within the variable domains, three hypervariable loops
037 from the heavy chain and three from the light chain—called complementarity-determining regions
038 (CDRs)—cluster together at the tip of the Fab to form the antigen-binding site, a spatially contiguous
039 surface on the antibody (paratopes) that engages the corresponding binding sites on the antigen
(epitopes), together forming the antibody-antigen (Ab-Ag) interfaces.

040 Identifying Ab-Ag interfaces is critical for vaccine design (Tarrahimofrad et al., 2021; Sarvmeili
041 et al., 2024), disease diagnosis (Ricci et al., 2023; Bourgonje et al., 2023), antibody engineering (Ku-
042 mar et al., 2024; Fantin et al., 2025) and research into immune evasion (Nabel et al., 2021; Liu et al.,
043 2022; Dejnirattisai et al., 2022; Liu et al., 2024), autoimmunity (Curran et al., 2023; Michalski et al.,
044 2024; Iversen et al., 2025) and immunotherapy (Bonaventura et al., 2022; Casirati et al., 2023; Shah
045 et al., 2025). Experimental techniques such as X-ray crystallography and cryo-electron microscopy
046 provide high-resolution Ab-Ag interactions but are resource-intensive (Brändén & Neutze, 2021;
047 Rubach et al., 2025). Phage display is faster but lacks atomic-level precision (Ledsgaard et al.,
048 2022). Therefore, many *in silico* methods have been developed to predict Ab-Ag interfaces.

049 Current computational methods for predicting Ab-Ag interfaces mainly follow two directions. The
050 first focuses on predicting interfaces using information from both antibodies and antigens. Repre-
051 sentative methods, including PECAN (Pittala & Bailey-Kellogg, 2020), Honda (Honda et al., 2020),
052 Epi-EPMP (Del Vecchio et al., 2021), PeSTo (Krapp et al., 2023), SEPPA-mAb (Qiu et al., 2023),
053 MIPE (Wang et al., 2024), DeepInterAware (Xia et al., 2025) and Epi4Ab (Tran et al., 2025), have
shown strong performance in predicting antibody-specific interfaces. The second direction aims




Figure 1: Interfaces sliding process. (A) Visualization of the SARS-CoV-2 Omicron BA.1 RBD in complex with the CAB-A17 antibody (PDB ID: 8C0Y). Interfaces are identified using a 4 Å distance cutoff (Appendix A). (B) Schematic of the interfaces sliding process.

to predict pan-epitopes on antigens in the absence of antibody information, thereby facilitating *de novo* antibody design for new antigens. Widely-adopted approaches, such as BepiPred-3.0 (Clifford et al., 2022), DiscoTope-3.0 (Høie et al., 2024) and SEMA 2.0 (Ivanisenko et al., 2024), have achieved comparatively better performance in large-scale B-cell epitope prediction.

However, accurate prediction of Ab–Ag interfaces remains challenging for several reasons. First, except Epi4Ab, current antibody-specific methods treat the antibody input as a whole without distinguishing heavy and light chains, which lacks physical interpretability as paratopes are formed by hypervariable loops from both VH and VL domains (Fig. 1A). Second, although some models (*e.g.*, Honda) employ cross-attention to capture Ab–Ag interactions, they struggle with dependencies that may be distracted by distant, irrelevant positions, given that Ab–Ag interfaces are confined to specific regions rather than spanning the entire sequence. Third, antibody-agnostic epitope prediction are limited by the scarcity of experimentally solved 3D structures. Although BepiPred-3.0 and SEMA-1D 2.0 are sequence-based methods, they underperform compared to structure-based or multi-modal methods.

Therefore, we design a sequence-based method that represents the Ab–Ag complex as three components—Ab-H, Ab-L and Ag—to predict Ab–Ag interfaces when antibodies are provided, and pan-epitopes from antigen alone. To capture both local patterns and long-range dependencies of a single biosequence, we adopt the Conformer architecture that combines convolution and self-attention (Gulati et al., 2020). To further capture interactions between biosequences, we introduce sliding attention into our model (Feng et al., 2024). Unlike conventional cross-attention, sliding attention accounts for spatial proximity and iteratively adjusts relative positions between two sequences, thereby uncovering more stable interaction patterns. In our cases, the antigen sequence first slides against Ab-H, and then Ab-L, generating an attention map for each sliding process (Fig. 1B).

To summarize, we propose **ABConformer**, an interfaced-based explainable AntiBody target prediction model with physics-inspired sliding-attention Conformer architecture. ABConformer has several advantages. First, it achieves a comprehensive improvement in predicting antibody-specific interfaces, while also outperforming all sequence-based methods in identifying antibody-agnostic epitopes on the SARS-CoV-2 dataset filtered from 2024 onwards. Second, it simulates the molecular docking process, providing a physically interpretable view of Ab–Ag interactions and pairwise residue relationships. Third, it enables large-scale prediction of Ab–Ag interfaces in the absence of 3D structures, which is particularly valuable in vaccine development, where numerous viral variants, multiple antigenic targets and candidate antibodies need to be assessed.

2 METHODS

2.1 SLIDING ATTENTION

Sliding attention is motivated by the physical process of molecular docking, where a biosequence dynamically slides along its partner to maximize the stability of interactions (Feng et al., 2024). It computes attention from both feature similarity and spatial proximity, iteratively updating antigen

108 residues first along the interaction gradients of Ab-H, then along those of Ab-L, thereby accurately
 109 capturing the features of Ab–Ag interfaces. An algorithm is provided in Appendix B.
 110

111 **Feature attention.** Consider a sliding sequence $X^{(t)} = \{x_1^{(t)}, x_2^{(t)}, \dots, x_m^{(t)}\}$ and a reference se-
 112 quence $Y^{(t)} = \{y_1^{(t)}, y_2^{(t)}, \dots, y_n^{(t)}\}$, where t is the iteration step and the residue embeddings satisfy
 113 $x_i^{(t)}, y_j^{(t)} \in \mathbb{R}^d$. To capture the feature similarity, embeddings are first projected into learnable latent
 114 spaces using linear maps $E_S, E_R \in \mathbb{R}^{d \times d}$, which yields the projected embeddings $X^{(t)} E_S \in \mathbb{R}^{m \times d}$
 115 and $Y^{(t)} E_R \in \mathbb{R}^{n \times d}$. The pairwise attention score $A_{ij}^{(t)}$ is then computed as:
 116

$$a_{ij}^{(t)} = \frac{(x_i^{(t)} E_S) \cdot (y_j^{(t)} E_R)^\top}{\sqrt{d}}, \quad (1)$$

$$A_{ij}^{(t)} = \exp \left(a_{ij}^{(t)} - \max_{k \in [1, n]} a_{ik}^{(t)} \right).$$

122 Here, each row of the scaled dot-product matrix is shifted by its maximum to prevent numerical over-
 123 flow. The exponential scores then lie in $(0, 1]$, providing non-negative affinities between residues.
 124

125 **Spatial attention.** The spatial proximity matrix $S^{(t)} \in \mathbb{R}^{m \times n}$ is estimated using a Gaussian kernel
 126 over the sequence positions. Assuming that the reference positions $Q = (q_1, \dots, q_n)$ are fixed
 127 integers along Y , and the sliding positions $P^{(t)} = (p_1^{(t)}, \dots, p_m^{(t)})$ are learnable positions of X at
 128 iteration t , the spatial attention score $S_{ij}^{(t)}$ is written as:
 129

$$S_{ij}^{(t)} = \exp \left(-\frac{(p_i^{(t)} - q_j)^2}{2h^2} \right). \quad (2)$$

132 Here, h is the bandwidth determined by the length of the reference sequence Y . A smaller h restricts
 133 the receptive field, causing sliding residues at $p_i^{(t)}$ to be attracted to less distant residues in Y , thereby
 134 confining each sliding process to a specific region. Assuming a binary mask $M \in \{0, 1\}^{m \times n}$, where
 135 $M_{ij} = 1$ if (i, j) is valid and 0 if padding. The bandwidth h is determined by the valid length of Y ,
 136 scaled by a factor c , and constrained to the range $[h_{\min}, h_{\max}]$:

$$h = \min \left\{ h_{\max}, \max \left\{ h_{\min}, \sum_{j=1}^n \frac{M_{:,j}}{c} \right\} \right\}. \quad (3)$$

140 **Weighted attention.** After obtaining feature and spatial attention, the weighted attention matrix is
 141 computed as the Hadamard product of them:
 142

$$W_{ij}^{(t)} = M_{ij} (A^{(t)} \odot S^{(t)})_{ij}. \quad (4)$$

144 Here, W captures the combined affinity between residues of the sliding and reference sequences,
 145 with higher values indicating stronger potential interactions. Since W is unnormalized, we perform
 146 row-wise and column-wise normalization to convert it into convex combination weights suitable for
 147 attention aggregation:

$$\widehat{W}_{ij}^{(t)} = \frac{W_{ij}^{(t)}}{\sum_{k=1}^n W_{ik}^{(t)} + \varepsilon}, \quad \widetilde{W}_{ij}^{(t)} = \frac{W_{ij}^{(t)}}{\sum_{k=1}^m W_{kj}^{(t)} + \varepsilon}, \quad (5)$$

151 where ε is a small constant added for numerical stability. Row-normalization ensures that each
 152 sliding residue x_i distributes its attention over the reference residues y_j , and column-normalization
 153 guarantees that each reference residue aggregates contributions from all sliding residues.

154 **Embedding updates.** Using the normalized attention weights, residue embeddings are iteratively
 155 updated via cross-attention with residual connections:
 156

$$X^{(t+1)} = \widehat{W}^{(t)} (Y^{(t)} E_Y) + X^{(t)}, \quad (6)$$

$$Y^{(t+1)} = (\widetilde{W}^{(t)})^\top (X^{(t)} E_X) + Y^{(t)}.$$

159 Here, $E_X, E_Y \in \mathbb{R}^{d \times d}$ are linear projections mapping embeddings into value spaces. Each sliding
 160 residue in $X^{(t)}$ queries all residues in $Y^{(t)}$ through $\widehat{W}^{(t)}$, aggregating contextual information, and
 161 similarly, each residue in $Y^{(t)}$ aggregates information from $X^{(t)}$ via $\widetilde{W}^{(t)}$.




Figure 2: Overview of the ABConformer architecture, comprising (I) an encoding layer, (II) Conformer layers, and (III) sliding attention modules. Six layers of stage II and III are stacked in the standard ABConformer (Appendix E). MHSA denotes multi-head self-attention.

Position updates. Finally, the sliding positions themselves are refined according to the attention distribution, which is computed as:

$$P^{(t+1)} = \widehat{W}^{(t)} Q. \quad (7)$$

An equivalent expression of this process is (Appendix B):

$$p_i^{(t+1)} - p_i^{(t)} = \sum_{j=1}^n \widehat{W}_{ij}^{(t)} (q_j - p_i^{(t)}). \quad (8)$$

Here, the update can be intuitively understood as each residue in the sliding sequence being ‘pulled’ toward regions where the reference residues collectively exert stronger interactions. Each reference residue contributes to this movement proportionally to its weighted attention, so residues naturally migrate toward positions of higher cumulative affinity. Conceptually, this process is analogous to mean-shift mode seeking (Cheng, 1995), where each iteration shifts residue x_i along the gradient of an underlying density function. In our case, this density is the accumulated interaction magnitude at the current position: $f(p_i^{(t)}) = \sum_j M_{ij} A_{ij}^{(t)} S_{ij}^{(t)}$. And x_i moves along the gradient of $f(p_i^{(t)})$.

2.2 ABCONFORMER

ABConformer adopts a three-branch architecture for Ab-H, Ab-L and the antigen (Fig. 2). In the antigen branch, sequence embeddings are first encoded using ESM-2 150M (Lin et al., 2023), followed by a feedforward layer and a multi-head self-attention (MHSA) module (Vaswani et al., 2017) both with residual connections (He et al., 2016). The antigen embeddings then interact with Ab-H and Ab-L through sliding, iteratively updating both the embeddings (Eq. 6) and sequence positions (Eq. 7). After T steps, this process produces two sets of antigen embeddings, $X_H^{(T)}$ and $X_L^{(T)}$, which are linearly combined as

$$X_{\text{Ag}} = \alpha X_H^{(T)} + (1 - \alpha) X_L^{(T)}, \quad (9)$$

where $\alpha \in [0, 1]$ is a weight controlling the contributions of Ab-H and Ab-L. The combined embedding X_{Ag} is then passed to the remaining Conformer stage, followed by a convolution block and an additional feed-forward layer both with residual connections.

The Ab-H and Ab-L branches are structurally similar, except that the MHSA module is omitted, as it contributes little to paratope prediction when sliding is applied (Appendix G). In the standard ABConformer, six layers of this three-branch backbone (except the encoding part) are stacked, balancing the computational cost with predictive performance (Appendix E).

216 3 EXPERIMENTS
217218 3.1 EXPERIMENTS SETUP
219220 **Dataset.** The training set of ABConformer was obtained from AACDB (Zhou et al., 2025), which
221 contains 7,488 experimentally solved structures. A single PDB entry may contain multiple identical
222 complexes arising from repeated copies in the crystal or multiple asymmetric units in the unit cell.
223 To remove redundant entries while retaining a diverse collection of Ab-Ag samples, we selected
224 only one complex per PDB ID, resulting in the final dataset of 3,674 entries. Then we analyzed all
225 antigens from the 3,674 entries and constructed a phylogenetic tree with ClustalOmega (Sievers &
226 Higgins, 2018), resulting in six clusters (Appendix D). Each cluster was then evenly divided into
227 five parts, and one part of each cluster was combined to form a fold. In this way, five folds were
228 generated for cross-validation.
229230 To further evaluate our model compared with other baselines, we extracted an external dataset of
231 SARS-CoV-2 from CoV-AbDab (Raybould et al., 2021). The SARS-CoV-2 set, filtered since 2024,
232 comprises 35 solved structures that has no overlap with the original training data (Appendix D).233 **Embedding and Interface Labeling.** Each complex was rigorously decomposed into one Ab-H,
234 Ab-L and Ag chain. Each chain was then embedded using ESM-2 150M to generate a representation
235 of 640 dimensions. Paratopes and epitopes were identified using a 4 Å distance cutoff between heavy
236 atoms of antibody and antigen chains (Van Regenmortel, 2009).237 **Training and Evaluation.** ABConformer was initially trained and evaluated via five-fold cross-
238 validation on the AACDB dataset, then retrained on the full dataset to capture more patterns. After
239 retraining, its performance was compared with multiple state-of-the-art methods on the SARS-CoV-
240 2 dataset.241 **Performance metrics.** To assess the performance of paratope and epitope predictions, we computed
242 two types of metrics (Appendix C). First, binary classification metrics, including intersection over
243 union (IoU), precision (Prec), recall (Rec), F1 score, and Matthews correlation coefficient (MCC).
244 Second, score-based metrics, including Pearson correlation coefficient (PCC), and the areas under
245 the receiver operating characteristic (ROC) and precision-recall (PR) curves. Higher values of these
246 metrics indicate better predictive performance.
247

Target	Method	IoU↑	Prec↑	Rec↑	F1↑	MCC↑	PCC↑	ROC↑	PR↑
Ab-Ag <i>Para</i>	PECAN	0.373	0.520	0.569	0.543	0.497	0.516	0.869	0.527
	Honda	0.414	0.595	0.578	0.586	0.565	0.591	0.885	0.595
	Epi-EPMP	0.406	0.608	0.551	0.578	0.550	0.573	0.893	0.584
	PeSTo	0.419	0.573	0.610	0.591	0.572	0.594	0.904	0.602
	MIPE	0.466	0.705	0.580	<u>0.636</u>	0.603	<u>0.620</u>	0.912	0.638
	DeepInterAware	0.430	0.645	0.563	<u>0.601</u>	0.585	0.605	<u>0.907</u>	0.614
	Epi4Ab	-	-	-	-	-	-	-	-
	AF2 Multimer	0.403	0.527	0.630	0.574	0.542	-	-	-
	ABConformer	0.482	0.693	0.613	0.651	0.622	0.632	0.904	0.651
Ab-Ag <i>Epi</i>	PECAN	0.230	0.311	0.470	0.374	0.342	0.397	0.885	0.302
	Honda	0.260	0.340	0.517	0.413	0.407	0.458	0.914	0.357
	Epi-EPMP	0.248	0.329	0.505	0.398	0.389	0.441	0.897	0.341
	PeSTo	0.243	0.307	0.539	0.391	0.379	0.424	0.907	0.326
	MIPE	<u>0.311</u>	0.412	0.560	<u>0.475</u>	<u>0.463</u>	<u>0.496</u>	0.923	0.419
	DeepInterAware	0.273	0.364	0.523	<u>0.429</u>	0.414	0.469	0.915	0.369
	Epi4Ab	0.305	<u>0.423</u>	0.521	0.467	0.457	0.493	<u>0.928</u>	0.415
	AF2 Multimer	0.215	0.275	0.496	0.354	0.307	-	-	-
	ABConformer	0.336	0.467	<u>0.545</u>	0.503	0.492	0.510	0.931	0.441
Ag <i>Epi</i>	BepiPred-3.0	0.077	0.087	0.403	0.143	0.162	0.187	<u>0.862</u>	0.094
	SEMA-1D 2.0	0.082	0.089	0.510	0.152	0.164	0.195	<u>0.804</u>	0.107
	DiscoTope-3.0	0.161	<u>0.194</u>	<u>0.487</u>	0.277	0.273	0.325	0.870	0.231
	ABConformer	0.144	0.197	0.348	<u>0.252</u>	<u>0.248</u>	0.283	0.855	<u>0.192</u>

263 Table 1: Comparison of antibody-specific methods (Ab-Ag, evaluated on paratopes and epitopes)
264 and antibody-agnostic methods (Ag, evaluated on epitopes) on the SARS-CoV-2 dataset. The best-
265 performing values are highlighted in bold, and the second-best values are underlined.
266

270 3.2 COMPARISON EXPERIMENTS
271

272 To evaluate the performance of predicting antibody-specific interfaces, we selected PECAN, Honda,
273 Epi-EPMP, PeSTo, MIPE, DeepInterAware and Epi4Ab as baseline methods. Each method was
274 evaluated on the SARS-CoV-2 dataset to assess the performance in predicting Ab-Ag interfaces.
275 Furthermore, since AlphaFold2 Multimer (Mirdita et al., 2022) is widely used for predicting protein
276 complex structures, many previous studies have extracted interfaces based on its structural predictions
277 (DeRoo et al., 2024; Clifford et al., 2025). Here, we also used AlphaFold2 Multimer v3 to
278 model all complexes and identified interface residues with a 4 Å distance cutoff, enabling a direct
279 comparison of ABConformer with commonly used tools.

280 To further assess pan-epitope prediction on antigens, we compared ABConformer with BepiPred-
281 3.0, DiscoTope-3.0 and SEMA-1D 2.0. Both BepiPred-3.0 and SEMA-1D 2.0 are sequence-based
282 methods for conformational epitope prediction, while DiscoTope-3.0 relies on antigen PDB struc-
283 tures. Here, the input for ABConformer only contains antigen sequences, with antibody embeddings
284 set to zero, yielding a classic Conformer architecture (*i.e.*, the sliding-attention module has no effect)
285 for epitope prediction.

286 Results show that ABConformer comprehensively improves the prediction of paratopes and epitopes
287 compared to all antibody-specific methods, as measured by IoU, F1, MCC, PCC and PR (Tab. 1).
288 Notably, epitope precision is increased by 0.044 relative to the second-best method, indicating that
289 the sliding process enhances the accurate docking between antigen and antibody chains. Further-
290 more, when antibody information is ignored, ABConformer outperforms current sequence-based
291 antibody-agnostic methods in pan-epitope prediction across IoU, F1, MCC, PCC and PR (Tab. 1).
292 However, the recall is substantially lower than that of other methods. This is attributed to two factors.
293 First, different methods were trained and evaluated using different datasets and epitope identification
294 protocols (Appendix F). Second, ABConformer trades off recall to achieve a substantial improve-
295 ment in precision.

296 3.3 ABLATION STUDIES
297

298 To dissect the components of ABConformer, we performed ablation studies from three perspectives:
299 encoding, sliding attention mechanism, and Conformer modules, which also correspond to three
300 stages (I, III, II) as shown in Figure 2. We first replaced the ESM-2 encoding with one-hot encoding
301 that represents each residue along with its 15 upstream and downstream neighbors, resulting in
302 a 651-dimensional feature vector (21 dimensions per residue \times 31 residues in context window).
303 This dimensionality was slightly higher than the 640-dimensional embeddings produced by ESM-2
304 150M. Then we compared sliding attention with conventional cross-attention, which lacks distance
305 constraints (Eq. 2) and position updates (Eq. 7), as well as with MHSA without chain interactions.
306 Finally, we ablated the Conformer backbone by selectively removing either the convolutional blocks
307 or the MHSA modules. Each variant was evaluated on the AACDB dataset using cross-validation,
308 with metrics demonstrating the mean values of five folds.

311	I: Encoding		III: Attention		II: Conformer		Ag					Ab-H	Ab-L	
	one-hot	ESM-2	self	cross	slide	Conv	MHSA	Prec \uparrow	Rec \uparrow	PCC \uparrow	ROC \uparrow	PR \uparrow	PCC \uparrow	PCC \uparrow
312	\times	\checkmark	\times	\times	\checkmark	\checkmark	\checkmark	0.660	0.546	0.611	0.906	0.589	0.741	0.697
313	\checkmark	\times	\times	\times	\checkmark	\checkmark	\checkmark	0.499	0.490	0.536	0.892	0.502	0.737	0.691
314	\times	\checkmark	\checkmark	\times	\times	\checkmark	\checkmark	0.469	0.453	0.485	0.877	0.415	0.736	0.675
315	\times	\checkmark	\checkmark	\times	\times	\checkmark	\checkmark	0.543	0.588	0.581	0.903	0.562	0.739	0.691
316	\times	\checkmark	\times	\checkmark	\times	\checkmark	\checkmark	0.557	0.539	0.572	0.901	0.539	0.735	0.687
317	\times	\checkmark	\times	\times	\checkmark	\times	\checkmark	0.610	0.559	0.597	0.905	0.576	0.739	0.693
318	\times	\checkmark	\times	\times	\checkmark	\checkmark	\times	0.460	0.447	0.484	0.859	0.411	0.732	0.667
319	\times	\checkmark	\times	\times	\times	\checkmark	\times							

320 321 Table 2: Ablation studies of ABConformer on antibody-specific interface prediction. The mean
322 metrics of five-fold cross-validation were evaluated on the AACDB dataset (N=3,674) across differ-
323 ent encoding strategies (stage I), attention mechanisms (stage III) and Conformer modules (stage II)
(Appendix G).




Figure 3: Sensitivity analysis. The box plots show the distribution of metrics from the last twenty training epochs, evaluated on epitopes using the same validation set and random seed (Appendix H). Analyses correspond to (A) sliding step T , (B) bandwidth scaling factor c , (C) maximum bandwidth h_{max} and (D) minimum bandwidth h_{min} (see METHODS). Default values are indicated in pink.

Here, we analyze the results in two parts: paratope prediction and epitope prediction. For antibody-specific paratope prediction, each variant attains slightly lower performance of paratope prediction on the AACDB dataset (Tab. 2). Variants that remove all attention mechanisms or replace sliding attention with self-attention show notable decreases in predictive performance on Ab-L.

For epitope prediction, each component of ABCFormer makes a substantial contribution to the overall performance (Tab. 2). In stage I, ESM-2 embeddings considerably outperform one-hot encoding in predictive performance and input dimensionality. In stage II, removing either convolution blocks or MHSA modules results in modest performance degradation. In stage III, replacing sliding attention with MHSA markedly reduces predictive performance, while substituting it with cross-attention increases recall by 0.042. This is because sliding attention guides antigen residues toward more stable binding configurations limited by the bandwidth, resulting in more conservative scores when two residues are too far apart; while cross-attention distributes interactions across entire sequences, where distant and irrelevant features can inflate attention scores for residues. However, in general, sliding attention achieves superior precision and also outperforms in PCC, ROC and PR.

3.4 SENSITIVITY ANALYSIS

In METHODS, we introduced sliding attention along with several hyperparameters, including the number of sliding steps (T), the bandwidth scaling factor (c), and the maximum and minimum bandwidths (h_{max} , h_{min}). Here, we varied these hyperparameters while keeping all other training settings unchanged to assess their influence on the overall model. Experiments were conducted on a fold (Fold 0) of AACDB dataset (Appendix D), training on 2,939 Ab-Ag complexes and evaluating on 735 complexes, all using the same random seed. The results were reported on the validation




Figure 4: Case study. (A-D) Weighted attention maps from the final sliding step: left, antigen with Ab-H; right, antigen with Ab-L. Color bars attached to the axes indicate the true interface positions. (A,B) 7yvl; (C,D) 8bg6. (E-F) Structural visualization of interface predictions for 7yvl and 8bg6. Surfaces in yellow, blue and green correspond to the antigen, Ab-H and Ab-L, respectively.

set from epochs 40 to 60, which showed the predictive capability near convergence (Appendix E). Additional analyses are provided in Appendix H.

As shown in Figure 3, three key observations can be drawn. First, increasing the number of sliding steps T progressively improves predictive precision, with three iterations showing the best overall performance in our settings. Second, a smaller bandwidth h tends to improve precision by down-weighting the contributions of more distant residues, while reducing recall since these residues may still carry relevant information (Eq. 3). Third, the overall performance shows minor fluctuations across the hyperparameter ranges considered, indicating the robustness of the sliding-attention algorithm in our tasks.

3.5 CASE STUDY

To illustrate the interpretability of our model, we selected two examples of weighted attention maps (Eq. 4) and structural visualizations from the SARS-CoV-2 test set. The attention maps show that ABCConformer accurately captures three CDRs on VH (*i.e.*, CDR-H1, CDR-H2 and CDR-H3) as

432 well as CDRs on VL, with strong attention scores concentrated on these regions (Fig. 4A-D). Fur-
 433 thermore, ABCConformer highlights antigen residues that are highly related and proximal to the an-
 434 tibody CDRs (Fig. 4A-D). The structural visualizations further demonstrate the high precision and
 435 recall achieved by our model in predicting Ab-Ag interfaces (Fig. 4E,F).

437 4 RELATED WORK

438 **Antibody-specific interface prediction methods.** PECAN integrates graph representation, graph
 439 convolution, attention, and transfer learning to model Ab-Ag structural relationships and context-
 440 ually predict interfaces (Pittala & Bailey-Kellogg, 2020). Honda’s work introduces convolution
 441 encoders, transformer encoders and a cross-transformer encoder into the backbone, achieving a
 442 multi-task model that simultaneously predicts antibody paratopes and antigen epitopes (Honda et al.,
 443 2020). Epi-EPMP employs a graph attention network (GAT) with fully connected layers to capture
 444 structural cues on antibodies and antigens (Del Vecchio et al., 2021). PeSTo is a parameter-free
 445 geometric transformer that directly encodes protein structures as atomic point clouds, using pair-
 446 wise geometry and multi-head attention to update atom-level scalar and vector states for binding site
 447 prediction (Krapp et al., 2023). MIPE uses multi-modal contrastive learning (CL)—intra-modal CL
 448 to separate binding and non-binding residues within each modality, and inter-modal CL to align se-
 449 quence and structure representations—along with multi-head attention layers that compute attention
 450 matrices for antibodies and antigens to capture their interaction patterns (Wang et al., 2024). Deep-
 451 InterAware can evaluate Ab-Ag affinity, identify binding sites, and predict the binding free energy
 452 changes due to mutations. Its Interaction Interface-aware Learner (ILL) embeds antigens with ESM-
 453 2 and antibodies with AbLang (Olsen et al., 2022), using bilinear attention and convolution blocks to
 454 capture interfaces of Ab-Ag complexes (Xia et al., 2025). Epi4Ab encodes antigen sequences with
 455 ESM-2 and antibody CDRs with AntiBERTy (Ruffolo et al., 2021), and integrates them with struc-
 456 tural features of Ab-Ag into residual interaction graphs, a graph attention network then classifying
 457 residues as epitopes, potential epitopes or non-epitopes (Tran et al., 2025).

458 **Antibody-agnostic epitope prediction methods.** BepiPred-3.0 uses ESM-2 embeddings as input
 459 to a feedforward neural network (FFNN) to predict both linear and conformational B-cell epitopes
 460 (Clifford et al., 2022). DiscoTope-3.0 uses inverse folding representations from ESM-IF1 (Hsu et al.,
 461 2022) and is trained on both predicted and solved structures using a positive-unlabelled ensemble
 462 strategy, enabling structure-based B-cell epitope prediction (Høie et al., 2024). SEMA-1D 2.0 adds a
 463 fully-connected layer on an ensemble of five ESM-2 models, while SEMA-3D 2.0 follows the same
 464 design but replaces ESM-2 with pre-trained Structure-aware Protein language models (SaProt) (Su
 465 et al., 2023; Ivanisenko et al., 2024).

467 5 CONCLUSION

468 In this study, we propose ABCConformer, an interface prediction model based on the sliding-attention
 469 Conformer architecture. The experimental results highlight three key findings. First, ABCConformer
 470 demonstrates improvement in several key metrics (e.g., F1 and PCC) for antibody-specific interface
 471 prediction and surpasses widely used sequence-based methods in antibody-agnostic epitope pre-
 472 diction. Second, the sliding-attention algorithm considerably improves the precision of antibody-
 473 specific epitope prediction while keeping the overall performance at a high level. Third, ABCCon-
 474 former produces interpretable attention maps for antigen-Ab-H and antigen-Ab-L interactions, with
 475 feature and spatial attention accurately capturing epitopes and paratopes within the CDRs.

476 **Future work.** Several avenues remain to be explored. First, previous antibody-specific methods
 477 have incorporated antibody embedding techniques such as AntiBERTy (Ruffolo et al., 2021) and
 478 AbLang (Olsen et al., 2022); assessing the effectiveness of such embeddings is important for opti-
 479 mizing ABCConformer. Second, ABCConformer need further evaluation on additional datasets with
 480 experimentally resolved structures, and its utility in practical applications requires validation. Third,
 481 pan-epitope prediction still leaves substantial room for improvement. Note that in this study, we sim-
 482 plly set antibody embeddings to zero to assess the performance of pan-epitope prediction, while this
 483 task does not benefit from either the antibody branches or the sliding-attention modules. As fu-
 484 ture work, we intend to develop a pure Conformer architecture dedicated to antigen sequences, and
 485 further examine how convolution and self-attention individually support epitope prediction.

486 REPRODUCIBILITY STATEMENT
487488 Training details are provided in Appendix E. All code and data will be made publicly available upon
489 acceptance.

490

491 REFERENCES
492493 Paola Bonaventura, Vincent Alcazer, Virginie Mutez, Laurie Tonon, Juliette Martin, Nicolas Chuvin,
494 Emilie Michel, Rasha E Boulos, Yann Estornes, Jenny Valladeau-Guilemond, et al. Identification
495 of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic t cells for
496 cancer immunotherapy. *Science Advances*, 8(4):eabj3671, 2022.497 Arno R Bourgonje, Sergio Andreu-Sánchez, Thomas Vogl, Shixian Hu, Arnau Vich Vila, Ranko
498 Gacesa, Sigal Leviatan, Alexander Kurilshikov, Shelley Klompus, Iris N Kalka, et al. Phage-
499 display immunoprecipitation sequencing of the antibody epitope repertoire in inflammatory bowel
500 disease reveals distinct antibody signatures. *Immunity*, 56(6):1393–1409, 2023.501 Gisela Brändén and Richard Neutze. Advances and challenges in time-resolved macromolecular
502 crystallography. *Science*, 373(6558):eaba0954, 2021.503 Gabriele Casirati, Andrea Cosentino, Adele Mucci, Mohammed Salah Mahmoud, Iratxe Ugarte Za-
504 bala, Jing Zeng, Scott B Ficarro, Denise Klatt, Christian Brendel, Alessandro Rambaldi, et al.
505 Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. *Nature*, 621(7978):
506 404–414, 2023.507 Yizong Cheng. Mean shift, mode seeking, and clustering. *IEEE transactions on pattern analysis
508 and machine intelligence*, 17(8):790–799, 1995.509 510 Joakim Nøddeskov Clifford, Magnus Haraldson Høie, Sebastian Deleuran, Bjoern Peters, Morten
511 Nielsen, and Paolo Marcatili. Bepipred-3.0: Improved b-cell epitope prediction using protein
512 language models. *Protein Science*, 31(12):e4497, 2022.513 514 Joakim Nøddeskov Clifford, Eve Richardson, Bjoern Peters, and Morten Nielsen. Abeptope-1.0:
515 Improved antibody target prediction by use of alphafold and inverse folding. *Science Advances*,
516 11(24):eadu1823, 2025.517 Ashley M Curran, Alexander A Girgis, Yura Jang, Jonathan D Crawford, Mekha A Thomas, Ryan
518 Kawalerski, Jeff Coller, Clifton O Bingham III, Chan Hyun Na, and Erika Darrah. Citrullination
519 modulates antigen processing and presentation by revealing cryptic epitopes in rheumatoid
520 arthritis. *Nature communications*, 14(1):1061, 2023.521 Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, Jiří Zahradník, Piyada Supasa, Chang Liu,
522 Helen ME Duyvesteyn, Helen M Ginn, Alexander J Mentzer, Aekkachai Tuekprakhon, et al.
523 Sars-cov-2 omicron-b. 1.1. 529 leads to widespread escape from neutralizing antibody responses.
524 *Cell*, 185(3):467–484, 2022.525 Alice Del Vecchio, Andreea Deac, Pietro Liò, and Petar Veličković. Neural message passing for
526 joint paratope-epitope prediction. *arXiv preprint arXiv:2106.00757*, 2021.527 528 Jacob DeRoo, James S Terry, Ning Zhao, Timothy J Stasevich, Christopher D Snow, and Brian J
529 Geiss. Pabfold: linear antibody epitope prediction using alphafold2. *bioRxiv*, 2024.530 531 Raianna F Fantin, Meng Yuan, Seok-Chan Park, Bailey Bozarth, Hallie Cohn, Maxinne Ignacio,
532 Patricia Earl, Alesandro Civljak, Gabriel Laghlali, Ding Zhang, et al. Human monoclonal antibodies
533 targeting a35 protect from death caused by mpox. *Cell*, 2025.534 535 Ziyang Feng, Jingyang Chen, Youlong Hai, Xuelian Pang, Kun Zheng, Chenglong Xie, Xiujuan
536 Zhang, Shengqing Li, Chengjuan Zhang, Kangdong Liu, et al. Sliding-attention transformer neu-
537 ral architecture for predicting t cell receptor–antigen–human leucocyte antigen binding. *Nature
Machine Intelligence*, 6(10):1216–1230, 2024.538 539 Anmol Gulati, James Qin, Chung-Cheng Chiu, Niki Parmar, Yu Zhang, Jiahui Yu, Wei Han, Shibo
Wang, Zhengdong Zhang, Yonghui Wu, et al. Conformer: Convolution-augmented transformer
for speech recognition. *arXiv preprint arXiv:2005.08100*, 2020.

540 Kaiming He, Xiangyu Zhang, Shaoqing Ren, and Jian Sun. Deep residual learning for image recognition.
 541 In *Proceedings of the IEEE conference on computer vision and pattern recognition*, pp.
 542 770–778, 2016.

543 Magnus Haraldson Høie, Frederik Steensgaard Gade, Julie Maria Johansen, Charlotte Würtzen, Ole
 544 Winther, Morten Nielsen, and Paolo Marcatili. Discotope-3.0: improved b-cell epitope prediction
 545 using inverse folding latent representations. *Frontiers in immunology*, 15:1322712, 2024.

546 Shion Honda, Kyohei Koyama, and Kamiya Kotaro. Cross attentive antibody-antigen interaction
 547 prediction with multi-task learning. In *2021 ICML Workshop on Computational Biology*, 2020.

548 Chloe Hsu, Robert Verkuil, Jason Liu, Zeming Lin, Brian Hie, Tom Sercu, Adam Lerer, and Alexander
 549 Rives. Learning inverse folding from millions of predicted structures. In *International conference on machine learning*, pp. 8946–8970. PMLR, 2022.

550 Nikita V Ivanisenko, Tatiana I Shashkova, Andrey Shevtsov, Maria Sindeeva, Dmitriy Umerenkov,
 551 and Olga Kardymon. Sema 2.0: web-platform for b-cell conformational epitopes prediction using
 552 artificial intelligence. *Nucleic Acids Research*, 52(W1):W533–W539, 2024.

553 Rasmus Iversen, Julie Elisabeth Heggelund, Saykat Das, Lene S Høydahl, and Ludvig M Sollid.
 554 Enzyme-activating b-cell receptors boost antigen presentation to pathogenic t cells in gluten-
 555 sensitive autoimmunity. *Nature Communications*, 16(1):2387, 2025.

556 Lucien F Krapp, Luciano A Abriata, Fabio Cortés Rodriguez, and Matteo Dal Peraro. Pesto:
 557 parameter-free geometric deep learning for accurate prediction of protein binding interfaces. *Nature
 558 communications*, 14(1):2175, 2023.

559 Anand Kumar, Francis Duffieux, Marie Gagnaire, Chiara Rapisarda, Thomas Bertrand, and Alexey
 560 Rak. Structural insights into epitope-paratope interactions of a monoclonal antibody targeting
 561 ceacam5-expressing tumors. *Nature Communications*, 15(1):9377, 2024.

562 Line Ledsgaard, Anne Ljungars, Charlotte Rimbault, Christoffer V Sørensen, Tulika Tulika, Jack
 563 Wade, Yessica Wouters, John McCafferty, and Andreas H Laustsen. Advances in antibody phage
 564 display technology. *Drug Discovery Today*, 27(8):2151–2169, 2022.

565 Zeming Lin, Halil Akin, Roshan Rao, Brian Hie, Zhongkai Zhu, Wenting Lu, Nikita Smetanin,
 566 Robert Verkuil, Ori Kabeli, Yaniv Shmueli, et al. Evolutionary-scale prediction of atomic-level
 567 protein structure with a language model. *Science*, 379(6637):1123–1130, 2023.

568 Lihong Liu, Sho Iketani, Yicheng Guo, Jasper F-W Chan, Maple Wang, Liyuan Liu, Yang Luo, Hin
 569 Chu, Yiming Huang, Manoj S Nair, et al. Striking antibody evasion manifested by the omicron
 570 variant of sars-cov-2. *Nature*, 602(7898):676–681, 2022.

571 Yuanchen Liu, Xiaoyu Zhao, Jialu Shi, Yajie Wang, Huan Liu, Ye-Fan Hu, Bingjie Hu, Huiping
 572 Shuai, Terrence Tsz-Tai Yuen, Yue Chai, et al. Lineage-specific pathogenicity, immune evasion,
 573 and virological features of sars-cov-2 ba. 2.86/jn. 1 and eg. 5.1/hk. 3. *Nature communications*, 15
 574 (1):8728, 2024.

575 Kevin Michalski, Taha Abdulla, Sam Kleeman, Lars Schmidl, Ricardo Gómez, Noriko Simorowski,
 576 Francesca Vallese, Harald Prüss, Manfred Heckmann, Christian Geis, et al. Structural and func-
 577 tional mechanisms of anti-nmdar autoimmune encephalitis. *Nature structural & molecular biol-*
 578 *ogy*, 31(12):1975–1986, 2024.

579 Milot Mirdita, Konstantin Schütze, Yoshitaka Moriwaki, Lim Heo, Sergey Ovchinnikov, and Martin
 580 Steinegger. Colabfold: making protein folding accessible to all. *Nature methods*, 19(6):679–682,
 581 2022.

582 Katherine G Nabel, Sarah A Clark, Sundaresh Shankar, Junhua Pan, Lars E Clark, Pan Yang, Adrian
 583 Coscia, Lindsay GA McKay, Haley H Varnum, Vesna Brusic, et al. Structural basis for continued
 584 antibody evasion by the sars-cov-2 receptor binding domain. *Science*, 375(6578):eabl6251, 2021.

585 Tobias H Olsen, Iain H Moal, and Charlotte M Deane. Ablang: an antibody language model for
 586 completing antibody sequences. *Bioinformatics Advances*, 2(1):vbac046, 2022.

594 Srivamshi Pittala and Chris Bailey-Kellogg. Learning context-aware structural representations to
 595 predict antigen and antibody binding interfaces. *Bioinformatics*, 36(13):3996–4003, 2020.
 596

597 Tianyi Qiu, Lu Zhang, Zikun Chen, Yuan Wang, Tiantian Mao, Caicui Wang, Yewei Cun, Genhui
 598 Zheng, Deyu Yan, Mengdi Zhou, et al. Seppa-mab: spatial epitope prediction of protein antigens
 599 for mabs. *Nucleic Acids Research*, 51(W1):W528–W534, 2023.

600 Matthew IJ Raybould, Aleksandr Kovaltsuk, Claire Marks, and Charlotte M Deane. Cov-abdab: the
 601 coronavirus antibody database. *Bioinformatics*, 37(5):734–735, 2021.
 602

603 Alejandro D Ricci, Leonel Bracco, Emir Salas-Sarduy, Janine M Ramsey, Melissa S Nolan, M Katie
 604 Lynn, Jaime Altcheh, Griselda E Ballering, Faustino Torrico, Norival Kesper, et al. The try-
 605 panosoma cruzi antigen and epitope atlas: antibody specificities in chagas disease patients across
 606 the americas. *Nature communications*, 14(1):1850, 2023.

607 Paweł Rubach, Karolina A Majorek, Michał Gucwa, Krzysztof Murzyn, Alexander Włodawer, and
 608 Wladek Minor. Advances in cryo-electron microscopy (cryoem) for structure-based drug discov-
 609 ery. *Expert Opinion on Drug Discovery*, 20(2):163–176, 2025.

610 Jeffrey A Ruffolo, Jeffrey J Gray, and Jeremias Sulam. Deciphering antibody affinity maturation
 611 with language models and weakly supervised learning. *arXiv preprint arXiv:2112.07782*, 2021.
 612

613 Javad Sarvmeili, Bahram Baghban Kohnehrouz, Ashraf Gholizadeh, Dariush Shanelbandi, and
 614 Hamideh Ofoghi. Immunoinformatics design of a structural proteins driven multi-epitope can-
 615 didate vaccine against different sars-cov-2 variants based on fynomeric. *Scientific reports*, 14(1):
 616 10297, 2024.

617 Masaud Shah, Muhammad Hussain, and Hyun Goo Woo. Structural insights into antibody-based
 618 immunotherapy for hepatocellular carcinoma. *Genomics & Informatics*, 23(1):1, 2025.
 619

620 Fabian Sievers and Desmond G Higgins. Clustal omega for making accurate alignments of many
 621 protein sequences. *Protein Science*, 27(1):135–145, 2018.

622 Jin Su, Chenchen Han, Yuyang Zhou, Junjie Shan, Xibin Zhou, and Fajie Yuan. Saprot: Protein
 623 language modeling with structure-aware vocabulary. *BioRxiv*, pp. 2023–10, 2023.
 624

625 Hossein Tarrahimofrad, Somayeh Rahimnahal, Javad Zamani, Ehsan Jahangirian, and Saeed Am-
 626 inzadeh. Designing a multi-epitope vaccine to provoke the robust immune response against in-
 627 fluenza a h7n9. *Scientific Reports*, 11(1):24485, 2021.

628 Nhan Dinh Tran, Krithika Subramani, and Chinh Tran-To Su. Epi4ab: a data-driven prediction
 629 model of conformational epitopes for specific antibody vh/vl families and cdrs sequences. In
 630 *mAbs*, volume 17, pp. 2531227. Taylor & Francis, 2025.

631 Marc HV Van Regenmortel. What is a b-cell epitope? In *Epitope Mapping Protocols: Second
 632 Edition*, pp. 3–20. Springer, 2009.
 633

634 Ashish Vaswani, Noam Shazeer, Niki Parmar, Jakob Uszkoreit, Llion Jones, Aidan N Gomez,
 635 Łukasz Kaiser, and Illia Polosukhin. Attention is all you need. *Advances in neural informa-
 636 tion processing systems*, 30, 2017.

637 Zhiwei Wang, Yongkang Wang, and Wen Zhang. Improving paratope and epitope prediction
 638 by multi-modal contrastive learning and interaction informativeness estimation. *arXiv preprint
 639 arXiv:2405.20668*, 2024.

640 Yuhang Xia, Zhiwei Wang, Feng Huang, Zhankun Xiong, Yongkang Wang, Minyao Qiu, and
 641 Wen Zhang. Deepinteraware: Deep interaction interface-aware network for improving antigen-
 642 antibody interaction prediction from sequence data. *Advanced Science*, 12(13):2412533, 2025.
 643

644 Yuwei Zhou, Wenwen Liu, Ziru Huang, Yushu Gou, Siqi Liu, Lixu Jiang, Yue Yang, and Jian
 645 Huang. A comprehensive antigen-antibody complex database unlocking insights into interaction
 646 interface. *eLife*, 14:RP104934, 2025.
 647

648 STATEMENT OF LLM USAGE
649650 Large Language Models (LLMs) were only used to polish the language of this paper. No LLM was
651 used to generate research ideas, experiments, or analyses.
652653 A ANTIBODY-ANTIGEN INTERFACES
654655 **Antibody structure.** A crystal structure of
656 mouse immunoglobulin G (IgG) is shown on
657 the right (Fig. 5), with the paired variable
658 domains at both Fab tips having the ability to in-
659 teract with specific antigens.
660661 **Interface identification.** Ab-Ag interfaces
662 play a critical role in determining binding
663 specificity and affinity. During immune recog-
664 nition, epitopes are typically composed of mul-
665 tiple spatially adjacent residues. To capture
666 this interaction, the notions of residue-neighbor
667 and residue-patch were introduced. A residue-
668 neighbor is defined when the minimum dis-
669 tance between heavy atoms of two residues is
670 less than 4 Å, and a residue-patch refers to a
671 group of residues whose atoms lie within 10
672 Å of a central residue. To identify the inter-
673 action residues between the antibody and anti-
674 gen, we focused on the residue-neighbor rela-
675 tionship, which is given as:
676

677
$$\min_{a \in r_i, b \in r_j} \|a - b\| < 4 \text{ Å}, \quad (10)$$


678 where r_i and r_j are residues from the antigen
679 and antibody chains respectively, and a, b rep-
680 resent the heavy atoms within these residues.681 **CDRs.** Antigen-binding sites are located on the VH and VL domains, where the interacting regions
682 are primarily the CDRs, particularly CDR-H3. The remainder of the variable domain, outside the
683 CDRs, is structurally well conserved and often referred to as the *framework region*. Antibody design
684 is commonly formulated as the task of selecting CDR sequences that optimally conform to a given
685 framework region. In the case study, we show that weighted attention maps of sliding attention
686 accurately capture three CDRs in VH domains, which demonstrates the applicability of our model
687 in identifying functional CDRs.
688
689
690
691
692
693
694
695
696
697
698
699
700
701

Figure 5: Cartoon representation of a full-length immunoglobulin (PDB ID: 1IGT), with domains annotated. Two identical heavy chains are shown in yellow and blue, and the identical light chains are shown in pink and green.

702 **B SLIDING ATTENTION**
703

704 **Equation 8.** The position update for sliding attention is defined in Equation 7 as
705

706
$$P^{(t+1)} = \widehat{W}^{(t)} Q,$$

707

708 where $\widehat{W}^{(t)} \in \mathbb{R}^{m \times n}$ is the row-normalized weighted attention matrix, and $Q \in \mathbb{R}^n$ represents the
709 fixed reference sequence positions. Expanding by rows, the update of the i -th sliding residue is:
710

711
$$p_i^{(t+1)} = \sum_{j=1}^n \widehat{W}_{ij}^{(t)} q_j. \quad (11)$$

712

713 The displacement from the previous position can be expressed as:
714

715
$$p_i^{(t+1)} - p_i^{(t)} = \sum_{j=1}^n \widehat{W}_{ij}^{(t)} q_j - p_i^{(t)}. \quad (12)$$

716

717 Since $\widehat{W}^{(t)}$ is row-normalized, i.e., $\sum_{j=1}^n \widehat{W}_{ij}^{(t)} = 1$, we can factor out $p_i^{(t)}$ to recover Equation 8 in
718 the main text:
719

720
$$p_i^{(t+1)} - p_i^{(t)} = \sum_{j=1}^n \widehat{W}_{ij}^{(t)} (q_j - p_i^{(t)}).$$

721

722 **Algorithm.** Here, an algorithm of sliding attention for a sliding sequence X and reference sequence
723 Y is shown below:
724

725

Algorithm 1: Sliding Attention

726 **Input:** Sliding embeddings $X^{(0)}$, reference embeddings $Y^{(0)}$, initial positions $P^{(0)}$, reference
727 positions Q , mask M , linear projections E_S, E_R, E_X, E_Y , iteration steps T , bandwidth
728 constraints h_{\min}, h_{\max} , scaling factor c , small constant ε .
729

730 **Output:** $X^{(T)}, Y^{(T)}, \widehat{W}_{ij}^{(T)}, \widetilde{W}_{ij}^{(T)}$.
731

732 01: $h \leftarrow \min\{h_{\max}, \max\{h_{\min}, \sum_{j=1}^n M_{:,j} / c\}\}$ (Eq. 3);
733

734 02: **for** $t = 0$ **to** $T - 1$ **do**

735 03: // also for all $i \in [1, m]$ and $j \in [1, n]$;
736 04: // feature attention (Eq. 1);
737 05: $a_{ij}^{(t)} \leftarrow (x_i^{(t)} E_S) \cdot (y_j^{(t)} E_R)^\top / \sqrt{d}$;
738 06: $A_{ij}^{(t)} \leftarrow \exp(a_{ij}^{(t)} - \max_k a_{ik}^{(t)})$;
739 07: // spatial attention (Eq. 2);
740 08: $S_{ij}^{(t)} \leftarrow \exp(- (p_i^{(t)} - q_j)^2 / 2h^2)$;
741 09: // weighted attention (Eq. 4, 5);
742 10: $W_{ij}^{(t)} \leftarrow M_{ij} (A^{(t)} \odot S^{(t)})_{ij}$;
743 11: $\widehat{W}_{ij}^{(t)} \leftarrow W_{ij}^{(t)} / (\sum_k W_{ik}^{(t)} + \varepsilon)$;
744 12: $\widetilde{W}_{ij}^{(t)} \leftarrow W_{ij}^{(t)} / (\sum_k W_{kj}^{(t)} + \varepsilon)$;
745 13: // Update sliding embeddings and reference embeddings (Eq. 6);
746 14: $X^{(t+1)} \leftarrow \widehat{W}^{(t)} (Y^{(t)} E_Y) + X^{(t)}$;
747 15: $Y^{(t+1)} \leftarrow (\widetilde{W}^{(t)})^\top (X^{(t)} E_X) + Y^{(t)}$;
748 16: // Update sliding positions (Eq. 7);
749 17: $P^{(t+1)} \leftarrow \widehat{W}^{(t)} Q$;
750

751 18: **return** $X^{(T)}, Y^{(T)}, \widehat{W}_{ij}^{(T)}, \widetilde{W}_{ij}^{(T)}$.

752
753
754
755

756 **C PERFORMANCE METRICS**
 757

758 **Binary predictions.** In the main text, we report intersection over union (IoU), precision (Prec),
 759 recall (Rec), F1 score and Matthews correlation coefficient (MCC) for paratope and epitope predic-
 760 tions. These metrics quantify the agreement between predicted and true binding sites after binariza-
 761 tion, with higher values indicating better predictive performance:
 762

$$763 \quad \text{IoU} = \frac{\text{TP}}{\text{TP} + \text{FP} + \text{FN}}$$

$$764$$

$$765$$

$$766 \quad \text{Prec} = \frac{\text{TP}}{\text{TP} + \text{FP}}$$

$$767$$

$$768$$

$$769 \quad \text{Rec} = \frac{\text{TP}}{\text{TP} + \text{FN}}$$

$$770$$

$$771$$

$$772 \quad \text{F1} = 2 \cdot \frac{\text{Prec} \cdot \text{Rec}}{\text{Prec} + \text{Rec}}$$

$$773$$

$$774$$

$$775 \quad \text{MCC} = \frac{\text{TP} \cdot \text{TN} - \text{FP} \cdot \text{FN}}{\sqrt{(\text{TP} + \text{FP})(\text{TP} + \text{FN})(\text{TN} + \text{FP})(\text{TN} + \text{FN})}}$$

$$776$$

$$777$$

778 where TP, TN, FP and FN denote true positives, true negatives, false positives and false negatives.
 779

780 **Score predictions.** Metrics that can be computed from continuous prediction scores include Pearson
 781 correlation coefficient (PCC), areas under the receiver operating characteristic (ROC) and precision-
 782 recall (PR) curves, Brier score and binary cross-entropy (BCE). These metrics assess the probabilis-
 783 tic calibration and ranking quality of predictions, which are computed as follows:
 784

$$785 \quad \text{PCC} = \frac{\text{Cov}(y_i, \hat{y}_i)}{\sigma_{y_i} \sigma_{\hat{y}_i}}$$

$$786$$

$$787 \quad \text{ROC-AUC} = \int_0^1 \text{TPR}(t) d\text{FPR}(t)$$

$$788$$

$$789$$

$$790 \quad \text{PR-AUC} = \int_0^1 \text{Prec}(t) d\text{Rec}(t)$$

$$791$$

$$792$$

$$793 \quad \text{Brier} = \frac{1}{N} \sum_{i=1}^N (y_i - \hat{y}_i)^2$$

$$794$$

$$795$$

$$796$$

$$797 \quad \text{BCE} = -\frac{1}{N} \sum_{i=1}^N [y_i \log(\hat{y}_i) + (1 - y_i) \log(1 - \hat{y}_i)]$$

$$798$$

$$799$$

800 Here, $y_i \in \{0, 1\}$ is the true label of residue i , $\hat{y}_i \in [0, 1]$ is the predicted score, and N is the
 801 total number of residues. The threshold $t \in [0, 1]$ is used to binarize the predicted scores when
 802 computing TPR, FPR, Rec and Prec, which are defined as $\text{TPR}(t) = \frac{\text{TP}(t)}{\text{TP}(t) + \text{FN}(t)}$, $\text{FPR}(t) =$
 803 $\frac{\text{FP}(t)}{\text{FP}(t) + \text{TN}(t)}$, $\text{Rec}(t) = \frac{\text{TP}(t)}{\text{TP}(t) + \text{FN}(t)}$, $\text{Prec}(t) = \frac{\text{TP}(t)}{\text{TP}(t) + \text{FP}(t)}$.
 804

805
 806
 807
 808
 809

810
811
812
813 D DATASET
814
815
816
817
818
819
820
821
822
823
824
825

Fold	Split	Ab-H		Ab-L		Ag	
		Avg. Len.	Int. Rate	Avg. Len.	Int. Rate	Avg. Len.	Int. Rate
0	Train	182.1	0.073	175.9	0.051	345.7	0.077
	Val	179.6	0.076	173.0	0.053	351.8	0.075
1	Train	181.8	0.074	175.3	0.052	345.6	0.076
	Val	180.9	0.072	175.5	0.051	352.4	0.077
2	Train	181.2	0.074	175.0	0.052	348.4	0.077
	Val	183.0	0.073	176.6	0.050	341.2	0.075
3	Train	181.7	0.073	175.5	0.051	346.9	0.076
	Val	181.2	0.074	175.0	0.052	347.0	0.077
4	Train	181.2	0.074	175.0	0.052	348.1	0.076
	Val	183.2	0.073	176.8	0.051	342.4	0.078

826
827
Table 3: Dataset statistics across 5-fold splits. For each fold, we report the average sequence length
and the average proportion of interfaces for Ab-H, Ab-L and Ag.


Fold	Cluster 1	Cluster 2	Cluster 3	Cluster 4	Cluster 5	Cluster 6	SUM
Fold 0	156	57	17	220	17	268	735
Fold 1	156	57	16	220	18	268	735
Fold 2	156	57	16	220	18	268	735
Fold 3	155	57	16	221	18	268	735
Fold 4	155	57	16	220	18	268	734


834
835
Table 4: Distribution of validation samples across clusters for each fold.
836

837
838
AACDB. The original 7,488 PDB struc-
839 tures were filtered to ensure that each
840 PDB ID appeared only once, resulting in
841 a final set of 3,674 complexes. Anti-
842 gen sequences were then extracted from
843 these complexes, and a phylogenetic tree
844 of the these sequences was constructed
845 using ClustalOmega. As shown in Figure
846 6, six clusters were identified based on
847 evolutionary relationships. Each cluster
848 was subsequently divided into five folds,
849 which were then combined to form the fi-
850 nal cross-validation datasets, yielding four
851 folds with 735 validation samples (2,939
852 training samples) and one fold with 734
853 validation samples (2,940 training sam-
854 ples) (Tab. 4). A detailed analysis of av-
855 erage sequence lengths and average inter-
856 face proportions for all chains is provided
857 in Table 3.


858 In practice, structures that do not distin-
859 guish Ab-H and Ab-L (*i.e.*, only the full
860 antibody sequence provided) exist. In such cases, we duplicate the chain into both Ab-H and Ab-L
861 to meet the input requirements of our model.

862
863
SARS-CoV-2. The SARS-CoV-2 dataset, filtered from CoV-AbDab since 2024, comprises 35 ex-
864 perimentally resolved PDB complexes. Among these, 12 antibodies can target pre-Omicron (SARS-
865 CoV-2 WT and its α , β variants, etc.), 4 can target Omicron, and 19 have the ability to target both
866 strains. By extracting the Ab-H, Ab-L and corresponding antigen chain from each complex, we
867 obtained 46 entries. This curated small dataset will be made publicly available.

868
Figure 6: Phylogenetic tree of antigens in the AACDB
3674 dataset, with six clusters obtained.

864 E TRAINING AND EVALUATION
865
866

880 Figure 7: Metrics across training epochs. Metrics were computed on the training set (N=3674)
881 every five epochs for Ab-H, Ab-L and Ag. Each reported value represents the mean calculated over
882 the corresponding epoch together with its two preceding and two succeeding epochs (a five-epoch
883 window). (A) BCE. (B) PCC.



907 Figure 8: Cross-validation across five folds. The (A-C) ROC-AUC and (D-F) PR-AUC curves are
908 plotted on Ab-H, Ab-L and Ag.
909

910 **Training details.** ABConformer was trained using per-residue cross-entropy loss with masking to
911 ignore padded positions. For a batch of sequences, the loss for each chain (Ab-H, Ab-L and Ag) is
912 independently computed as:

$$\mathcal{L}_{\text{chain}} = -\frac{1}{\sum_i m_i} \sum_i m_i \sum_c y_{i,c} \log \hat{y}_{i,c}, \quad (13)$$

913 where m_i is a binary mask for valid positions, $y_{i,c}$ is the one-hot target for position i and class c ,
914 and $\hat{y}_{i,c}$ is the predicted probability after softmax. The final loss is averaged across three chains:

Layer	Epoch	Ab-H		Ab-L		Ag		Param (M)	MACs (G)
		PCC↑	F1↑	PCC↑	F1↑	PCC↑	F1↑		
4	40-60	0.733	0.732	0.684	0.670	0.603	0.578	108.764	259.828
6	40-60	0.736	0.737	0.689	0.677	0.615	0.593	162.940	389.111
8	40-60	0.736	0.738	0.691	0.678	0.614	0.590	217.116	518.394

Table 5: Performance metrics across different layers of Conformer and sliding-attention. Each model was trained on fold 0 (Appendix D) and evaluated on the validation set at epochs 40–60, with the reported values representing the average over these twenty epochs. Params and MACs were calculated assuming a batch size of 2, and all sequences in the batch padded to a length of 512.

$$\mathcal{L} = \frac{1}{3} (\mathcal{L}_H + \mathcal{L}_L + \mathcal{L}_{Ag}). \quad (14)$$

Several optimization and stabilization techniques were also employed. First, the model parameters were optimized using AdamW with weight decay, and gradients were clipped to a maximum norm of 1.0 to prevent instability during backpropagation. Second, to reduce memory usage, we applied automatic mixed precision (AMP). Third, an exponential moving average (EMA) of the model weights was maintained throughout training, improving the stability of evaluation metrics. Finally, the learning rate and loss values were recorded at each iteration using a smoothed logging utility to monitor the optimization process.

The training process of the standard ABConformer (*i.e.*, six layers of stages II and III) on the full AACDB dataset is shown in Figure 7. Predictive performance for Ab-H and Ab-L converges around epoch 40, while Ag converges around epoch 50. This explains our choice of epochs 40–60 in the sensitivity analysis.

Five-fold cross-validation. In the ablation studies, all ABConformer variants were evaluated using five-fold cross-validation on the AACDB dataset. Here, we show the five-fold ROC and PR curves for the original ABConformer. As shown in Figure 8, the curves are plotted separately for Ab-H, Ab-L and Ag, indicating similar performance across folds. Notably, epitope prediction performance is consistently lower than that for paratopes. This suggests that the model accurately captures paratope residues within CDRs, and residues between CDRs receive less attention; While antigen binding sites are more variable, making them inherently more challenging for prediction.

Conformer and sliding-attention layers. A standard ABConformer consists of six layers of Conformer and sliding-attention modules (Fig. 2). To investigate the effect of model depth, we also explored different numbers of layers. As reported in Table 5, six layers provide the best trade-off between predictive performance and computational cost. Note that in this table, parameter counts (Params) and multiply-accumulate operations (MACs) were calculated using a batch size of 2 and a sequence length of 512. However, during actual training, dynamic sequence length padding was applied for each batch, and a batch size of 6 could be supported in our environment.


Configuration. A complete configuration is shown below:

Parameter	Value	Description
d_{model}	640	Embedding dim of input features.
dim_{ff}	1280	Hidden dim of feedforward modules.
n_{heads}	10	Number of attention heads.
$conv_kernel$	5	Kernel size of convolution modules.
n_{blocks}	6	Number of stacked blocks.
min_bw	48	Minimum bandwidth.
max_bw	144	Maximum bandwidth.
$scale$	3	Scaling factor for the bandwidth.
$sliding_step$	3	Number of sliding steps.
α	0.5	Weight for Ag update from Ab-H.

Table 6: Model configuration.

Env	Spec
OS	Linux 5.10.0-35
Python	3.9.23
CPU	24C / 48T
Memory	334 GB
GPU	4 × A100 (40GB)

Table 7: Environment configuration.

972 F COMPARISON EXPERIMENTS
973
974

1002 Figure 9: Metrics across thresholds evaluated on the SARS-CoV-2 dataset. The light-red dashed
1003 lines indicate the thresholds selected in the comparison experiments. (A–C) Antibody-specific
1004 interface prediction on Ab-H, Ab-L and Ag, respectively. (D) Antibody-agnostic epitope prediction
1005 on Ag.

1006
1007 **AlphaFold Multimer v3.** We used AlphaFold Multimer ColabFold v3 with 4 seeds, 5 models and 3
1008 recycles, generating 20 structures per complex. Then we selected the top-ranked predicted structure
1009 for each complex and extracted interfaces based on a 4 Å distance cutoff.

1010
1011 **Antibody-specific methods.** Open-source implementations of PECAN, Epi-EPMP, PeSTo, DeepInterAware
1012 and Epi4Ab are available on GitHub. PECAN, DeepInterAware and Epi4Ab were trained
1013 on the AACDB-3674 dataset (with Epi4Ab operating on Ab-H and Ab-L separately) and then evaluated
1014 on the SARS-CoV-2 dataset. For PeSTo, a parameter-free method with detailed usage guidelines,
1015 predictions were obtained by following the provided instructions. Epi-EPMP lacks detailed
1016 training code; therefore, we reconstructed the network following their paper and conducted the
1017 analysis. For the remaining baselines, we re-implemented their architectures following the descriptions
in the original publications.

1018
1019 **Antibody-agnostic methods.** BepiPred-3.0, DiscoTope-3.0 and SEMA 2.0 provide publicly available
1020 web platforms for direct use. SEMA-1D 2.0 adopts a 12 Å distance cutoff, achieving the highest
1021 recall (Tab. 1). SEMA-3D 2.0 provides a log-scaled score representing the expected number of
1022 contacts with antibody residues and annotations of predicted N-glycosylation sites, the interpretation of
1023 this score as a probability remains unclear. Hence, we did not report its results.

1023
1024 **ABCConformer.** Figure 9 shows metrics evaluated across different thresholds on the SARS-CoV-2
1025 dataset. The thresholds selected for classifying interfaces are 0.2, 0.13 and 0.3 for Ab-H, Ab-L and
Ag, respectively, and a threshold of 0.11 was chosen for antibody-agnostic epitope prediction.

1026 **G ABLATION**

Ab	Ab-H			Ab-L			Ag			Param (M)	MACs (G)
	F1↑	PCC↑	PR↑	F1↑	PCC↑	PR↑	F1↑	PCC↑	PR↑		
✗	0.738	0.741	0.770	0.679	0.697	0.702	0.597	0.611	0.589	162.940	389.111
✓	0.741	0.743	0.770	0.677	0.701	0.705	0.591	0.608	0.585	167.862	394.144

1033 Table 8: Ablation study of MHSA modules in antibody branches. Mean metrics of 5-fold cross-
1034 validation were evaluated on the AACDB dataset.

<i>ABCConformer</i>		IoU↑	Prec↑	Rec↑	F1↑	MCC↑	PCC↑	ROC↑	PR↑	Brier↓	BCE↓
Ab-H	fold 0	0.588	0.742	0.740	0.741	0.722	0.741	0.973	0.767	0.031	0.200
	fold 1	0.589	0.717	0.768	0.741	0.723	0.743	0.975	0.782	0.030	0.185
	fold 2	0.587	0.696	0.789	0.739	0.721	0.746	0.973	0.765	0.031	0.192
	fold 3	0.587	0.719	0.761	0.739	0.720	0.742	0.969	0.770	0.031	0.197
	fold 4	0.575	0.763	0.701	0.731	0.713	0.732	0.973	0.768	0.031	0.211
	AVG	0.585	0.727	0.752	0.738	0.720	0.741	0.973	0.770	0.031	0.197
Ab-L	fold 0	0.520	0.703	0.666	0.684	0.669	0.695	0.970	0.713	0.025	0.150
	fold 1	0.513	0.676	0.680	0.678	0.662	0.697	0.968	0.684	0.026	0.164
	fold 2	0.513	0.710	0.649	0.678	0.665	0.698	0.967	0.700	0.024	0.162
	fold 3	0.506	0.718	0.632	0.672	0.659	0.694	0.969	0.711	0.025	0.166
	fold 4	0.521	0.687	0.684	0.685	0.671	0.701	0.970	0.702	0.025	0.172
	AVG	0.514	0.699	0.662	0.679	0.665	0.697	0.969	0.702	0.025	0.163
Ag	fold 0	0.432	0.639	0.571	0.603	0.586	0.616	0.913	0.589	0.030	0.206
	fold 1	0.420	0.673	0.528	0.592	0.579	0.605	0.913	0.589	0.029	0.231
	fold 2	0.415	0.644	0.539	0.587	0.571	0.600	0.893	0.574	0.031	0.232
	fold 3	0.437	0.674	0.555	0.609	0.594	0.622	0.911	0.594	0.029	0.217
	fold 4	0.424	0.668	0.538	0.596	0.582	0.610	0.899	0.597	0.032	0.230
	AVG	0.426	0.660	0.546	0.597	0.583	0.611	0.906	0.589	0.030	0.223
<i>I: one-hot</i>		IoU↑	Prec↑	Rec↑	F1↑	MCC↑	PCC↑	ROC↑	PR↑	Brier↓	BCE↓
Ab-H	fold 0	0.572	0.687	0.774	0.728	0.708	0.741	0.974	0.760	0.031	0.134
	fold 1	0.571	0.705	0.751	0.727	0.707	0.738	0.970	0.761	0.031	0.147
	fold 2	0.570	0.707	0.746	0.726	0.705	0.733	0.973	0.757	0.032	0.154
	fold 3	0.569	0.716	0.734	0.725	0.705	0.732	0.961	0.739	0.031	0.185
	fold 4	0.572	0.691	0.768	0.728	0.708	0.739	0.971	0.757	0.030	0.146
	AVG	0.571	0.701	0.755	0.727	0.707	0.737	0.970	0.755	0.031	0.153
Ab-L	fold 0	0.502	0.651	0.687	0.669	0.653	0.693	0.967	0.688	0.024	0.104
	fold 1	0.510	0.672	0.680	0.676	0.660	0.694	0.964	0.695	0.025	0.122
	fold 2	0.505	0.632	0.716	0.671	0.655	0.691	0.967	0.690	0.026	0.118
	fold 3	0.511	0.664	0.689	0.676	0.661	0.689	0.951	0.683	0.024	0.158
	fold 4	0.502	0.675	0.663	0.669	0.653	0.687	0.964	0.699	0.023	0.127
	AVG	0.506	0.659	0.687	0.672	0.657	0.691	0.963	0.691	0.025	0.126
Ag	fold 0	0.324	0.486	0.492	0.489	0.464	0.536	0.896	0.507	0.033	0.141
	fold 1	0.319	0.535	0.441	0.483	0.463	0.536	0.891	0.507	0.034	0.164
	fold 2	0.294	0.447	0.461	0.454	0.427	0.496	0.886	0.453	0.036	0.150
	fold 3	0.362	0.514	0.550	0.532	0.508	0.559	0.890	0.520	0.035	0.188
	fold 4	0.341	0.511	0.507	0.509	0.485	0.551	0.898	0.526	0.034	0.149
	AVG	0.328	0.499	0.490	0.493	0.470	0.536	0.892	0.502	0.034	0.158
<i>III: cross-att</i>		IoU↑	Prec↑	Rec↑	F1↑	MCC↑	PCC↑	ROC↑	PR↑	Brier↓	BCE↓
Ab-H	fold 0	0.589	0.722	0.761	0.741	0.722	0.744	0.972	0.769	0.032	0.197
	fold 1	0.588	0.717	0.766	0.741	0.722	0.744	0.972	0.767	0.031	0.204
	fold 2	0.578	0.741	0.725	0.733	0.714	0.734	0.971	0.759	0.031	0.207
	fold 3	0.574	0.708	0.753	0.730	0.710	0.734	0.968	0.748	0.032	0.191
	fold 4	0.586	0.714	0.765	0.739	0.720	0.740	0.974	0.762	0.031	0.208
	AVG	0.583	0.721	0.754	0.737	0.718	0.739	0.971	0.761	0.031	0.201
Ab-L	fold 0	0.520	0.720	0.651	0.684	0.670	0.690	0.974	0.718	0.025	0.168
	fold 1	0.509	0.641	0.713	0.675	0.659	0.691	0.969	0.703	0.026	0.146
	fold 2	0.512	0.682	0.672	0.677	0.662	0.685	0.969	0.700	0.025	0.169
	fold 3	0.520	0.685	0.683	0.684	0.669	0.693	0.964	0.688	0.025	0.163
	fold 4	0.518	0.647	0.721	0.682	0.667	0.695	0.972	0.698	0.025	0.148
	AVG	0.516	0.675	0.688	0.680	0.666	0.691	0.970	0.701	0.025	0.159

1080	Ag	fold 0	0.401	0.552	0.594	0.572	0.551	0.595	0.912	0.554	0.033	0.215
1081		fold 1	0.395	0.541	0.595	0.567	0.546	0.578	0.916	0.578	0.035	0.221
1082		fold 2	0.385	0.543	0.570	0.556	0.534	0.575	0.903	0.575	0.035	0.217
1083		fold 3	0.399	0.553	0.590	0.571	0.550	0.584	0.896	0.544	0.034	0.219
1084		fold 4	0.386	0.527	0.591	0.557	0.535	0.572	0.891	0.556	0.032	0.224
1085		AVG	0.393	0.543	0.588	0.565	0.543	0.581	0.903	0.562	0.034	0.219
1086	<i>III: self-att</i>		IoU↑	Prec↑	Rec↑	F1↑	MCC↑	PCC↑	ROC↑	PR↑	Brier↓	BCE↓
1087	Ab-H	fold 0	0.587	0.716	0.765	0.740	0.720	0.741	0.972	0.771	0.032	0.218
1088		fold 1	0.575	0.719	0.741	0.730	0.711	0.730	0.971	0.743	0.030	0.192
1089		fold 2	0.577	0.713	0.751	0.731	0.712	0.729	0.970	0.740	0.033	0.212
1090		fold 3	0.587	0.738	0.742	0.740	0.721	0.739	0.971	0.774	0.031	0.241
1091		fold 4	0.588	0.720	0.763	0.741	0.722	0.741	0.971	0.769	0.032	0.224
1092		AVG	0.583	0.721	0.752	0.736	0.717	0.736	0.971	0.759	0.032	0.217
1093	Ab-L	fold 0	0.517	0.663	0.702	0.682	0.666	0.691	0.961	0.696	0.026	0.183
1094		fold 1	0.482	0.629	0.673	0.650	0.633	0.657	0.945	0.638	0.028	0.189
1095		fold 2	0.485	0.643	0.664	0.653	0.636	0.657	0.948	0.633	0.028	0.201
1096		fold 3	0.518	0.687	0.678	0.682	0.667	0.689	0.962	0.686	0.025	0.179
1097		fold 4	0.508	0.684	0.664	0.673	0.658	0.682	0.950	0.674	0.026	0.178
1098		AVG	0.502	0.661	0.676	0.668	0.652	0.675	0.953	0.665	0.026	0.186
1099	Ag	fold 0	0.310	0.485	0.462	0.473	0.449	0.495	0.875	0.425	0.037	0.245
1100		fold 1	0.292	0.431	0.475	0.452	0.425	0.466	0.874	0.393	0.039	0.239
1101		fold 2	0.288	0.462	0.434	0.448	0.422	0.482	0.875	0.414	0.034	0.214
1102		fold 3	0.302	0.501	0.431	0.464	0.441	0.487	0.879	0.419	0.036	0.231
1103		fold 4	0.303	0.467	0.463	0.465	0.440	0.495	0.882	0.425	0.036	0.231
1104		AVG	0.299	0.469	0.453	0.460	0.435	0.485	0.877	0.415	0.037	0.232
1105	<i>II: no conv</i>		IoU↑	Prec↑	Rec↑	F1↑	MCC↑	PCC↑	ROC↑	PR↑	Brier↓	BCE↓
1106	Ab-H	fold 0	0.565	0.700	0.746	0.722	0.701	0.733	0.970	0.749	0.032	0.163
1107		fold 1	0.567	0.720	0.728	0.724	0.704	0.734	0.971	0.760	0.030	0.166
1108		fold 2	0.566	0.720	0.726	0.723	0.703	0.730	0.968	0.738	0.031	0.163
1109		fold 3	0.578	0.709	0.757	0.732	0.713	0.739	0.964	0.739	0.031	0.170
1110		fold 4	0.579	0.713	0.755	0.734	0.714	0.739	0.970	0.748	0.031	0.168
1111		AVG	0.571	0.713	0.742	0.727	0.707	0.735	0.969	0.747	0.031	0.166
1112	Ab-L	fold 0	0.516	0.690	0.673	0.681	0.666	0.694	0.968	0.692	0.024	0.138
1113		fold 1	0.498	0.653	0.678	0.665	0.649	0.678	0.960	0.679	0.026	0.167
1114		fold 2	0.505	0.663	0.679	0.671	0.656	0.685	0.961	0.662	0.024	0.143
1115		fold 3	0.500	0.631	0.706	0.666	0.651	0.687	0.964	0.672	0.026	0.138
1116		fold 4	0.512	0.671	0.682	0.677	0.662	0.691	0.963	0.677	0.024	0.139
1117		AVG	0.506	0.662	0.684	0.672	0.657	0.687	0.963	0.676	0.025	0.145
1118	Ag	fold 0	0.379	0.547	0.553	0.550	0.528	0.580	0.906	0.551	0.032	0.181
1119		fold 1	0.379	0.560	0.539	0.549	0.529	0.572	0.895	0.534	0.032	0.195
1120		fold 2	0.367	0.560	0.517	0.537	0.516	0.558	0.900	0.518	0.034	0.210
1121		fold 3	0.398	0.607	0.537	0.570	0.551	0.599	0.904	0.575	0.030	0.192
1122		fold 4	0.359	0.510	0.548	0.529	0.505	0.552	0.898	0.516	0.036	0.215
1123		AVG	0.377	0.557	0.539	0.547	0.526	0.572	0.901	0.539	0.033	0.198
1124	<i>II: no MHSAs</i>		IoU↑	Prec↑	Rec↑	F1↑	MCC↑	PCC↑	ROC↑	PR↑	Brier↓	BCE↓
1125	Ab-H	fold 0	0.590	0.736	0.748	0.742	0.723	0.743	0.974	0.781	0.031	0.192
1126		fold 1	0.578	0.738	0.728	0.733	0.714	0.735	0.970	0.762	0.031	0.199
1127		fold 2	0.578	0.709	0.757	0.732	0.713	0.739	0.964	0.739	0.031	0.170
1128		fold 3	0.583	0.742	0.731	0.737	0.718	0.739	0.970	0.778	0.031	0.200
1129		fold 4	0.589	0.704	0.784	0.741	0.723	0.740	0.969	0.735	0.031	0.206
1130		AVG	0.584	0.726	0.749	0.737	0.718	0.739	0.970	0.759	0.031	0.193
1131	Ab-L	fold 0	0.508	0.667	0.681	0.674	0.658	0.691	0.960	0.673	0.027	0.167
1132		fold 1	0.522	0.640	0.738	0.686	0.672	0.695	0.973	0.699	0.026	0.162
1133		fold 2	0.500	0.631	0.706	0.666	0.651	0.693	0.964	0.672	0.026	0.148
1134		fold 3	0.512	0.674	0.681	0.678	0.662	0.694	0.969	0.711	0.025	0.153
1135		fold 4	0.511	0.670	0.683	0.676	0.661	0.693	0.968	0.672	0.025	0.165
1136		AVG	0.511	0.656	0.698	0.676	0.661	0.693	0.967	0.685	0.026	0.159
1137	Ag	fold 0	0.415	0.609	0.566	0.587	0.568	0.600	0.903	0.580	0.031	0.219
1138		fold 1	0.401	0.571	0.574	0.572	0.551	0.581	0.908	0.569	0.034	0.244
1139		fold 2	0.398	0.607	0.537	0.570	0.551	0.599	0.904	0.575	0.030	0.212
1140		fold 3	0.422	0.604	0.583	0.593	0.574	0.604	0.917	0.593	0.032	0.224
1141		fold 4	0.419	0.659	0.534	0.590	0.575	0.601	0.894	0.565	0.031	0.243
1142		AVG	0.411	0.610	0.559	0.582	0.564	0.597	0.905	0.576	0.032	0.229

<i>II, III: no att</i>		IoU↑	Prec↑	Rec↑	F1↑	MCC↑	PCC↑	ROC↑	PR↑	Brier↓	BCE↓
Ab-H	fold 0	0.572	0.705	0.753	0.728	0.708	0.732	0.946	0.730	0.033	0.221
	fold 1	0.578	0.706	0.761	0.732	0.713	0.735	0.956	0.734	0.031	0.215
	fold 2	0.575	0.705	0.757	0.730	0.711	0.734	0.958	0.730	0.031	0.196
	fold 3	0.564	0.704	0.740	0.721	0.701	0.728	0.957	0.722	0.032	0.204
	fold 4	0.571	0.711	0.743	0.727	0.707	0.733	0.951	0.724	0.031	0.199
	AVG	0.572	0.706	0.751	0.728	0.708	0.732	0.954	0.728	0.032	0.207
Ab-L	fold 0	0.493	0.638	0.684	0.660	0.644	0.676	0.932	0.639	0.026	0.165
	fold 1	0.473	0.611	0.676	0.642	0.625	0.661	0.927	0.623	0.027	0.178
	fold 2	0.484	0.647	0.657	0.652	0.636	0.674	0.929	0.654	0.025	0.148
	fold 3	0.471	0.624	0.658	0.640	0.623	0.660	0.927	0.624	0.026	0.157
	fold 4	0.477	0.652	0.640	0.646	0.629	0.666	0.930	0.633	0.025	0.154
	AVG	0.479	0.635	0.663	0.648	0.631	0.667	0.929	0.635	0.026	0.161
Ag	fold 0	0.302	0.475	0.453	0.464	0.439	0.490	0.864	0.417	0.036	0.222
	fold 1	0.287	0.436	0.457	0.446	0.420	0.479	0.860	0.403	0.036	0.218
	fold 2	0.283	0.438	0.444	0.441	0.413	0.474	0.861	0.398	0.038	0.225
	fold 3	0.300	0.483	0.443	0.462	0.437	0.492	0.850	0.418	0.036	0.246
	fold 4	0.294	0.471	0.439	0.454	0.429	0.487	0.863	0.420	0.037	0.234
	AVG	0.293	0.460	0.447	0.453	0.427	0.484	0.859	0.411	0.037	0.229

Table 9: Details of Ablation Studies. Performance of interface prediction was evaluated on Ab-H, Ab-L and Ag using five-fold cross-validation. AACDB (N=3,674; four folds with 735 validation complexes, one with 734). *Threshold: 0.33*.

Ablation of ABCConformer. Initially, we designed ABCConformer by integrating sliding attention into the Conformer architecture. However, the ablation of MHSA modules on the antibody branches indicates that MHSA contributes little to paratope prediction while increasing the computational cost (Tab. 8). The complete results of the ablation studies are shown in Table 9.

H SENSITIVITY ANALYSIS




Figure 10: Sensitivity analysis on (A) α (Eq. 9) and (B) convolution kernel.

Here, we further analyzed the weights for updating antigen embeddings after sliding with Ab-H and Ab-L, as well as the convolution kernel in the model (Fig. 10). The results indicate that biasing the weight toward Ab-H or Ab-L reduces epitope precision, while weights above 0.5 (favoring Ab-H) slightly improve recall. Additionally, large convolution kernels tend to overlook fine-grained features within interaction sites, thus decreasing overall performance.

I MORE CASES




Figure 11: More cases in the SARS-CoV-2 dataset. Surfaces colored in yellow, blue and green represent the antigen, Ab-H and Ab-L, respectively. (A) 7yvm. (B) 8gsb. (C) 8gou. The other pair of antibody chains in 8gou was hidden in the subfigure.

Additional SARS-CoV-2 prediction cases are shown in Figure 11. We further analyzed a complex containing multiple antibody chains (*i.e.*, two paired VH and VL domains) bound to the SARS-CoV-2 Omicron spike protein (PDB ID: 8gou). Since ABConformer requires only one Ab-H, Ab-L and the antigen as input, it additionally predicts pan-epitopes on all possible regions of the antigen. Notably, these pan-epitope predictions coincide with the true binding sites of the other antibody chains, highlighting the potential of our model to generalize to more complex Ab–Ag assemblies.